Tumor-specific T Cells
Tumor-specific T Cells - Related Videos
10:15
Isolation and Culture Expansion of Tumor-specific Endothelial Cells
0 Views •
Cited by 20 •
2015
We report a reliable method to isolate and culture primary tumor-specific endothelial cells from genetically engineered mouse models.
02:42
An In Vitro Assay to Evaluate the Anti-Tumor Activity of Tumor-Specific CAR T Cells
0 Views •
2025
This video demonstrates an in vitro assay to validate chimeric antigen receptor (CAR) T cell activity. B-cell lymphoma cells expressing CD19 antigen and cytoplasmic luciferase are co-cultured with CD19-specific CAR T cells. CAR binding to CD19 on a tumor induces the CAR T cells to release cytokines and toxins that cause tumor cell cytotoxicity. The CAR T cell activity is evaluated by quantifying the released cytokine and decreased luciferase-mediated bioluminescence in the tumor cells.
04:42
An Ex Vivo Technique to Generate Tumor-Specific Chimeric Antigen Receptor T Cells
0 Views •
2025
This video demonstrates a technique for the ex vivo generation of tumor antigen-specific chimeric antigen receptor (CAR) T cells. Retroviral vectors carrying transgenic RNA are mixed with spleen cells in a medium supplemented with interleukin-2 to promote T-cell survival and proliferation. The mixture is then transferred to a plate coated with recombinant human fibronectin fragments and centrifuged to facilitate the fusion of the virus with the cell, allowing the RNA to integrate into the host...
04:13
A Technique to Assess the In Vivo Localization of Tumor-Specific Antibodies
0 Views •
2025
This video demonstrates a technique to study the in vivo localization of tumor-specific antibodies in a mouse tumor xenograft model. Upon subcutaneously injecting cancer cells into mice for tumor formation, fluorescently-labeled antibodies are injected that bind to tumor-specific receptors, enabling in vivo assessment of antibody localization via imaging.
10:57
Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells
0 Views •
Cited by 4 •
2019
This article describes a method to generate functional tumor antigen-specific induced pluripotent stem cell-derived CD8αβ+ single positive T cells using OP9/DLL1 co-culture system.
FAQs
The key recognition event occurs when a T-cell receptor binds a tumor-derived peptide displayed by a major histocompatibility complex molecule. This peptide–MHC interaction provides the specificity needed to distinguish malignant tissue from healthy cells. Its effectiveness therefore depends on both the tumor antigen and its presentation, linking antigen recognition directly to selective immune activation.
After recognition, activated cells can release cytokines and direct target-cell destruction through perforin and granzymes. Perforin and granzymes are cytotoxic molecules that support the killing response, while cytokines provide an additional signaling output. Considering these activities together helps researchers evaluate antitumor function rather than treating recognition alone as evidence of effective tumor control.
Specificity does not guarantee a durable response. Tumors may lose or alter the antigen recognized by the T-cell receptor, reducing the target available for detection. In addition, immune suppression within the tumor environment can limit activity after recognition. These constraints explain why studies examine both antigen specificity and the conditions that determine whether Tumor-specific T cells remain effective.
Tumor-infiltrating lymphocytes, or TILs, provide a research context for examining T cells present within malignant tissue. Investigators study these cells alongside tumor immunity and adoptive cell therapy, asking whether their antitumor specificity can be expanded or genetically enhanced. This approach connects observations in tumors with strategies designed to strengthen targeted immune responses.
Adoptive cell therapies seek to improve antitumor responses by expanding Tumor-specific T cells or genetically enhancing their activity. Expansion can increase the population available for study or treatment, whereas genetic enhancement is intended to strengthen the antitumor response. These strategies are investigated because naturally occurring specificity may be insufficient when tumors lose antigens or suppress immunity.
Their study addresses how immune lymphocytes distinguish abnormal tissue, translate receptor recognition into cytokine release and cytotoxicity, and encounter resistance from antigen loss or immune suppression. Within immunology and infection research, this work contributes to tumor immunity studies, tumor-infiltrating lymphocyte investigations, and adoptive cell therapies. The shared focus is the regulation and effectiveness of targeted immune responses.